Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine: A multicenter, double-blind, placebo-controlled dose range-findings study

Neurology

Volumn 49, Issue 5, 1997, Pages 1210-1218

  Rapoport, A M ^a   Ramadan, N M ^b,h   Adelman, J U ^c   Mathew, N T ^d   Elkind, A H ^e   Kudrow, D B ^f   Earl, N L ^g  

^a NEW ENGLAND CENTER FOR HEADACHE   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c Adelman Headache Center   (United States)

^d Houston Headache Clinic   (United States)

^e Elkind Headache Center   (United States)

^f California Medical Clinic for Headache   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ZOLMITRIPTAN;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHENIA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PARESTHESIA; PHOTOPHOBIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SOMNOLENCE; TABLET; TREATMENT OUTCOME; VERTIGO;

EID: 0030657702     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.49.5.1210     Document Type: Article

References (19)

1. Goadsby PJ, Edvinsson L. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. Headache 1994;34:394-399.
2. 1D agonist drugs: selectively targeting additional sites of action. Eur Neurol 1996;36(suppl 2):13-18.
3. Kaube H, Hoskin KL, Goadsby PJ. Inhibition by sumatriptan of central trigeminal neurons only after blood-brain barrier disruption. Br J Pharmacol 1993;109:788-792.
4. Peck R, Dixon R, Seaber E, et al. Clinical pharmacology of 311C90. New Adv Headache Res 1994;4:9-10.
5. Lacey LF, Hussey EK, Fowler PA. The single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur J Clin Pharmacol 1995;47:543-548.
6. Seaber E, On N, Phillips S, Churchus R, Posner J, Rolan P. The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers. Br J Clin Pharmacol 1996;41:141-147.
7. Tfelt-Hansen P. Sumatriptan for the treatment of migraine attacks - a review of controlled clinical trials. Cephalalgia 1993;13:238-244.
8. Wilkinson M, Pfaffenrath V, Schoenen J, Diener H-C, Steiner TJ. Migraine and cluster headache - their management with sumatriptan: a critical review of the current clinical experience. Cephalalgia 1995;15:337-357.
9. Sargent J, Kirschner JR, Davies R, Kirkhart B. Oral sumatriptan is effective and well tolerated for the acute treatment of migraine: results of a multicenter study. Neurology 1995;45(suppl 7):S10-S14.
10. Cutler N, Mushet GR, Davis R, Clements B, Whitcher L. Oral sumatriptan for the acute treatment of migraine: Evaluation of three dosage strengths. Neurology 1995;45(suppl 7):S5-S9.
11. Tfelt-Hansen P. Oral sumatriptan [letter]. Neurology 1996;47: 612-613.
12. Dahlöf C, Diener HC, Goadsby P, et al. A multicenter, double-blind, placebo-controlled, dose-range finding study to investigate the efficacy and safety of oral doses of 311C90 in the acute treatment of migraines [abstract 19]. Headache 1995;35: 292.
13. 1D agonist in the acute oral treatment of migraine; a double-blind, placebo-controlled, dose-range finding study. Neurology 1996;46:522-526.
14. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8(suppl 7):19-21.
15. Lloyd K. The clinical profile of sumatriptan: safety and tolerability. Eur Neurol 1994;34(suppl 2):40-43.
16. 1B/1D receptor agonists. Neurology 1997;48(suppl 3):S21-S24.
17. Winner P, Lowy MT, Fletcher PE, for the International 311C90 Long-term Study Group. Confirmation of the long-term safety and efficiency of oral 311C in the acute treatment of migraine: demographic analysis from a study of >30000 treated attacks [abstract P405]. Eur J Neurol 1996;3(suppl 5):151.
18. Bousser MG, D'Allens H, Richard A, and the Early-Morning Migraine Sumatriptan Study Group. Efficacy of subcutaneous sumatriptan in the acute treatment of early-morning migraine. J Intern Med 1993;234:211-216.
19. Clarke CE, MacMillan L, Sondhi S, Wells NEJ. Economic and social impact of migraine. Q J Med 1996;89:77-84.